When will Quince report earnings and why does it matter for QNCX stock?

Quince Therapeutics announces results on **March 23 2026**; investors will look for cash runway, trial updates on eDSP, and management commentary. The report can trigger large intraday moves given low market cap and high event risk for QNCX stock.

What are the main financial red flags for QNCX stock?

Main red flags are negative EPS **-1.14**, low market cap **$4,883,267.00**, and tight cash per share **$0.49**. These increase the likelihood of financing needs, which often dilutes existing holders and pressures QNCX stock.

How should traders approach QNCX stock around earnings?

Traders should use small sizes, clear stop-losses and avoid heavy overnight exposure. Volume spikes and volatility indicators suggest fast moves; event-driven trading with strict risk controls suits QNCX stock best.

Does Meyka AI provide a forecast for QNCX stock?

Yes. Meyka AI's forecast model projects a quarterly figure of **$1.38**, implying large upside versus the current **$0.09**. Forecasts are model-based projections and not guarantees.

US Stocks

QNCX stock down 9.59% intraday (NASDAQ) March 20 2026: earnings week in focus

ByDanny Kontos March 20, 2026

QNCX stock is trading at $0.09 intraday on March 20 2026 after a -9.59% move that reflects heightened investor caution ahead of the company’s upcoming earnings update. Quince Therapeutics, Inc. (QNCX) on the NASDAQ (United States, USD) faces an earnings announcement on March 23 2026 that may change sentiment. Volume is active at 15,547,095 shares vs an average of 66,746,013, while market cap sits near $4,883,267.00. This earnings spotlight examines financials, trading metrics, recent corporate actions and the likely market reaction into the report.